



RESI REDEFINING
EARLY STAGE
INVESTMENTS

**Innovation Challenge Asia
2019 Award Winner**

COMPANY Moexa Pharmaceuticals Limited (Moexa) was founded in 2014 and presently has business offices in Hong Kong and the United States, and with R&D in the US.

GOAL The company actively seeking collaboration, investment and partnership opportunities that will accelerate getting products to market.

PRODUCT DEVELOPMENT The company's anti-cancer therapeutic [Cancelex™] has completed successful POC tests in 2020 and is undergoing IND preparations. The company's anti-fibrotic therapeutic has secured patent rights and is scheduled for collaborative testing with Dartmouth College.

BUSINESS Moexa focuses on development of proprietary inhibitors targeting TGFβ Smad3 signaling and developing related therapeutic solutions making use of its NCEs.

FUNDING The business roll out and commercialisation has been privately funded by the company's founders. The initial business to commercialise product development of lab tested anti-cancer Smad3 inhibitors resulted from R&D funding of US\$32m, including US\$17m from the NIH.

COLLABORATION The company has arranged a collaboration agreement with Dartmouth College in order to accelerate development of its anti-fibrotic therapeutics.

PATENT LIBRARY The company has a robust patent library covering mechanism-of-action for many cancers, and specified anti-fibrotic applications. The large patent portfolio includes granted or pending patents in the USA, Europe, China, Canada, Australia, India, and Hong Kong.

PEER REVIEW The company's patented Smad3 solution has been peer reviewed, with publication in Nature Communications, March 2017.

MANAGEMENT RESUME

| | | |
|-----------------------------------|---|---|
| 10 FDA IND Approvals | 1000s PATENTS Filed Globally | \$100m START UP Funds Raised |
|-----------------------------------|---|---|

Mr. ANTHONY DESIR Director, CEO: Investment Banking. Raised over \$2b in client and vertical funding, 40+ years experience. Hong Kong.

Dr. TIMOTHY LETTERS Director, Head of Patent Securitisation: Senior Patent Attorney, Patent Advisor to HK government and other major organisations, 30+ years experience. Hong Kong.

Dr. STEPHEN PORTER, Director, Chief Scientist: Leading pharmacologist and new product development specialist. 6 FDA IND approvals, 45+ years experience. USA.


Dr. HO YIN LO Director, Chief Research Scientist: Experienced new product development specialist and drug hunter. 4 FDA IND approvals, 25+ years experience. USA.

Mr. LAURENCE THOO Director, Head of Business Strategy: Leading regional patent advisor and consultant, including advisor to government and statutory bodies in Asia, 25+ years experience. Hong Kong.

PRODUCT

TGFβ cytokines regulate cell fate decisions during development, tissue homeostasis and regeneration, and are major players in tumorigenesis, fibrotic disorders, immune malfunctions and various congenital diseases. Phosphorylation of the Smad 2/3 complex is necessary for tumor development. Suppression of phosphorylation as demonstrated by Moexa's NCEs. has been shown to prevent and reverses tumorigenesis.

TGFβ - Smad3 Signalling Interaction Moexa's Clinically Proven Therapeutic Application



BENEFITS

Moexa's Cancelex™ NCE Smad3 inhibitor prevents tumor development with the following proven anti-cancer effects:

- ✓ Increases NK cell production
- ✓ Kills cancer cells
- ✓ Reduces Treg cells mediated cancer tolerance
- ✓ Reduces CD31, VEGF mediated angiogenesis
- ✓ Reduces MMP-2, -9, -13 CXCR4 mediated matrix degradation

Immune booster & proven cancer killer

PIPELINE PROPECTS

Effects of the TGFβ family are mediated by a combinatorial set of ligands and receptors and by a common set of receptor-activated mothers against decapentaplegic homologue (Smad) transcription factors in tumorigenesis.

Suppression of NK cell-mediated immuno surveillance via the Smad3-E4BP4 axis contributes to tumor development, cancer progression and/or fibrosis. Disruption of Smad3 is shown to reverse these effects with a common inhibitor becoming viable to address tumorigenesis in various types of diseases.

Moexa's NCEs demonstrate therapeutic efficacy as anti-fibrotics. These have been tested for pulmonary fibrosis following COVID infections and appear to have other similar anti-fibrotic applications.

CONTACT : info@moexa.com

www.moexa.com